Clinical Trial

Axillary Management in Breast Cancer Patients With Needle Biopsy Proven Nodal Metastases After Neoadjuvant Chemotherapy

Study acronym: ATNEC
Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to assess whether, omitting further axillary treatment (ALND and ART) for patients with early stage breast cancer and axillary nodal metastases on needle biopsy, who after NACT have no residual cancer in the lymph nodes on sentinel node biopsy, is non-inferior to axillary treatment in terms of disease free survival (DFS) and results in reduced risk of lymphoedema at 5 years.
Protocol Amendment History 18 amendments
This ClinicalTrials.gov record has been amended 18 times since 2019-09-27; most recent amendment 2026-03-27.
Status change: Not Yet Recruiting → Recruiting 2020-10-10
Trial Details
NCT Number NCT04109079
Lead Sponsor University Hospitals of Derby and Burton NHS Foundation Trust
Conditions Breast Cancer, Sentinel Lymph Node, Neoplasm, Breast
Enrollment 1,900 participants
Start Date 2021-02-26
Primary Completion 2030-02-28 (estimated)
Study Completion 2030-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-03-30